NCT01223209View on ClinicalTrials.gov

A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions

Carcinoma

Interventions

DRUG

LTX-315

0.25-2.0 mg/ML, maximum 5 injections during 36 days.

Trial Locations (1)

9038

University Hospital North-Norway, Tromsø

Sponsors

Lead Sponsor

Lytix Biopharma AS

All Listed Sponsors

collaborator

Kael-GemVax Co., Ltd.

INDUSTRY

lead

Lytix Biopharma AS

INDUSTRY

NCT01223209 - A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma | Biotech Hunter | Biotech Hunter